PubMedCrossRef 17 Jemal A, Siegel E, Ward E, Murray T, Xu J, Thu

PubMedCrossRef 17. Jemal A, Siegel E, Ward E, Murray T, Xu J, Thun MJ: Cancer stastistics. CA Cancer J Clin 2007, 57:43–66.PubMedCrossRef 18. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recruitment disease. Urol Clin North Am 2003, 30:843–852.PubMedCrossRef

19. Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55:851–863.PubMedCrossRef 20. Belldegrun AS: Renal cell carcinoma: prognostic factors and patient selection. Eur Urol Suppl 2007, 6:477–483.CrossRef 21. Wu XR, Sha JJ, Liu DM, Chen YH, Yang GL, Zhang J, Xhen YY, Bo JJ, Huang YR: High Rigosertib order expression of p53-induced ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma. Eur J Sur Oncol 2012, 39:100–106.CrossRef 22. Mosashvilli D, Kahl P, Mertens C, Holzapfel S, Rogenhofer S, Hauser S, Büttner R, Von Ruecker A, Müller SC, Ellinger J: Globle histone acetylation

levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 2010, 101:2664–2669.PubMedCrossRef 23. Edge SB, Byrd DR, Compton CC, Fritz AG, Selleckchem Veliparib Greene FL, Trotti A: AJCC Cancer Staging Manual. 7th edition. Chicago, IL: Springer; 2010. 24. Choschzick M, Oosterwijl R, Muller V, Woelber L, Simon R, Moch H, Tennstedt P: Overexpression of Epigenetics inhibitor carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 2011, 459:193–200.PubMedCrossRef 25. Tostain J, Li G, Gentil-Perret A, Gigante M: Carbonate Anidulafungin (LY303366) anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur J Cancer 2010, 46:3141–3148.PubMedCrossRef 26. Song JS, Chun

SM, Lee JY, Kim DK, Kim YH, Jang SJ: The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Korean J Pathol 2011, 45:386–396.CrossRef 27. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, daignosis, and therapy. Eur Urol 2010, 58:75–83.PubMedCrossRef 28. Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH: Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007, 96:104–109.PubMedCrossRef 29. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ: Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 2009, 115:1448–1458.PubMedCrossRef 30.

Comments are closed.